Molecular neurobiology of depression: PET findings on the elusive correlation with symptom severity

Frontiers in Psychiatry

Volumn 4, Issue MAR, 2013, Pages

  Smith, Donald F ^a   Jakobsen, Steen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain imaging; Depressive disorders; Negative emotions; Neurobiology; Neurotransmitters; Positron emission tomography; Reliability; Symptom severity

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMYLOID PROTEIN; ANTIDEPRESSANT AGENT; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTRANSMITTER; NICOTINIC RECEPTOR; PHOSPHODIESTERASE IV; RADIOLIGAND; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; TAU PROTEIN;

AMYLOID PLAQUE; BINDING AFFINITY; BRAIN FUNCTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HORMONE SYNTHESIS; HORMONE TRANSPORT; HUMAN; ISOTOPE LABELING; MOLECULAR NEUROBIOLOGY; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; RECEPTOR BINDING; REVIEW; SEROTONIN METABOLISM; SYMPTOM; TREATMENT RESPONSE;

EID: 84877718620     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00008     Document Type: Review

References (97)

1. Amsterdam, J. D., Winokur, A., Bryant, S., Larkin, J., and Rickels, K. (1983). The dexamethasone suppression test as a predictor of antidepressant response. Psychopharmacology (Berl.) 80, 43-45.
2. Bartels, A. L., de Klerk, O. L., Kortekaas, R., de Vries, J. J., and Leenders, K. L. (2010). 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr. Top. Med. Chem. 10, 1775-1784.
3. Bender, D., Olsen, A. K., Marthi, M. K., Smith, D. F., and Cumming, P. (2004). PET evaluation of the uptake of N-[11C]methyl CP-643,051, an NK1 receptor antagonist, in the living porcine brain. Nucl. Med. Biol. 31, 699-704.
4. Bhagwagar, Z., Rabiner, E. A., Sargent, P. A., Grasby, P. M., and Cowen, P. J. (2004). Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 9, 386-392.
5. Brody, A. L., Mandelkern, M. A., London, E. D., Olmstead, R. E., Farahi, J., Scheibal, D., et al. (2006). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch. Gen. Psychiatry 63, 907-915.
6. Brust, P., Scheffel, U., and Szabo, Z. (1999). Radioligands for the study of the 5-HT transporter in vivo. Idrugs 2, 129-145.
7. Brust, P., Zessin, J., Kuwabara, H., Pawelke, B., Kretzschmar, M., Hinz, R., et al. (2003). Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)(+)-McN5652. Synapse 47, 143-151.
8. Canli, T., and Lesch, K. P. (2007). Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci. 10, 1103-1109.
9. Cannon, D. M., Carson, R. E., Nugent, A. C., Eckelman, W. C., Kiesewetter, D. O., Williams, J., et al. (2006). Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 63, 741-747.
10. Cannon, D. M., Ichise, M., Rollis, D., Klaver, J. M., Gandhi, S. K., Charney, D. S., et al. (2007). Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry 62, 870-877.
11. Cannon, D. M., Klaver, J. K., Gandhi, S. K., Solorio, G., Peck, S. A., Erickson, K., et al. (2011). Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol. Psychiatry 16, 407-418.
12. Caraci, F., Copani, A., Nicoletti, F., and Drago, F. (2010). Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur. J. Pharmacol. 626, 64-71.
13. Collier, D. A., Stober, G., Li, T., Heils, A., Catalano, M., Di, B. D., et al. (1996). A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders[seecomments].Mol.Psychiatry 1, 453-460.
14. Curran-Everett, D. (2000). Multiple comparisons:philosophies and illustrations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1-R8.
15. Dani, J. A., and Bertrand, D. (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 47, 699-729.
16. de Klerk, O. L., Willemsen, A. T., Roosink, M., Bartels, A. L., Hendrikse, N. H., Bosker, F. J., et al. (2009). Locally increased Pglycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int. J. Neuropsychopharmacol. 12, 895-904.
17. Fisher, A. (2012). Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 22-33.
18. Frey, B. N., Skelin, I., Sakai, Y., Nishikawa, M., and Diksic, M. (2010). Gender differences in alpha-[(11)C]MTrp brain trapping, an index of serotonin synthesis, in medication-free individuals with major depressive disorder: a positron emission tomography study. Psychiatry Res. 183, 157-166.
19. Frisardi, V., Panza, F., and Farooqui, A. A. (2011). Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. Brain Res. Rev. 67, 344-355.
20. Frokjaer, V. G., Vinberg, M., Erritzoe, D., Svarer, C., Baare, W., Budtz-Joergensen, E., et al. (2009). High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 46, 360-366.
21. Fujita, M., Hines, C. S., Zoghbi, S. S., Mallinger, A. G., Dickstein, L. P., Liow, J. S., et al. (2012). Downregulation of brain phosphodiesterase type IV measured with (11)C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 72, 548-554.
22. Ginovart, N., Wilson, A. A., Meyer, J. H., Hussey, D., and Houle, S. (2001). Positron emission tomography quantification of [(11)C]DASB binding to the human serotonin transporter: modeling strategies. J. Cereb. Blood Flow Metab. 21, 1342-1353.
23. Gjedde, A., Wong, D. F., Rosa-Neto, P., and Cumming, P. (2005). Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int. Rev. Neurobiol. 63, 1-20.
24. Golde, T. E., Petrucelli, L., and Lewis, J. (2010). Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp. Neurol. 223, 252-266.
25. Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., et al. (2003). The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64, 1465-1475.
26. Hirschfeld, R. M. (2000). History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61(Suppl. 6), 4-6.
27. Hirvonen, J., Karlsson, H., Kajander, J., Lepola, A., Markkula, J., Rasi-Hakala, H., et al. (2008). Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY100635. Int. J. Neuropsychopharmacol. 11, 465-476.
28. Homberg, J. R., and Lesch, K. P. (2011). Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 69, 513-519.
29. Houle, S., Ginovart, N., Hussey, D., Meyer, J. H., and Wilson, A. A. (2000). Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur. J. Nucl. Med. 27, 1719-1722.
30. Ichise, M., Liow, J. S., Lu, J. Q., Takano, A., Model, K., Toyama, H., et al. (2003). Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 23, 1096-1112.
31. Innis,R. B.,Cunningham,V. J.,Delforge, J.,Fujita,M.,Gjedde,A.,Gunn,R. N., et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 1533-1539.
32. Jones, T., and Rabiner, E. A. (2012). The development, past achievements,and future directions of brain PET. J. Cereb. Blood Flow Metab. 32, 1426-1454.
33. Karlsson, H., Hirvonen, J., Kajander, J., Markkula,J.,Rasi-Hakala,H.,Salminen, J. K., et al. (2010). Research letter: psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol. Med. 40, 523-528.
34. Klumpers, U. M., Veltman, D. J., Drent, M. L., Boellaard, R., Comans, E. F., Meynen, G., et al. (2010). Reduced parahippocampalandlateraltemporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur. J. Nucl. Med. Mol. Imaging 37, 565-574.
35. Kumar, A., Kepe, V., Barrio, J. R., Siddarth, P., Manoukian, V., Elderkin-Thompson, V., et al. (2011). Protein binding in patients with late-life depression. Arch. Gen. Psychiatry 68, 1143-1150.
36. Laje, G., Cannon, D. M., Allen, A. S., Klaver, J. M., Peck, S. A., Liu, X., et al. (2010). Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int. J. Neuropsychopharmacol. 13, 715-724.
37. Lammertsma, A. A. (2002). Radioligand studies: imaging and quantitative analysis. Eur. Neuropsychopharmacol. 12, 513-516.
38. Lanzenberger, R., Baldinger, P., Hahn, A., Ungersboeck, J., Mitterhauser, M., Winkler, D., et al. (2013). Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol. Psychiatry 18, 93-100.
39. Laruelle, M. (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20, 423-451.
40. Laruelle, M., Slifstein, M., and Huang,Y. (2002). Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27, 287-299.
41. Lavretsky, H., Siddarth, P., Kepe, V., Ercoli, L. M., Miller, K. J., Burggren, A. C., et al. (2009). Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am. J. Geriatr. Psychiatry 17, 493-502.
42. Mann, J. J., Huang, Y. Y., Underwood, M. D., Kassir, S. A., Oppenheim, S., Kelly,T. M.,et al. (2000). A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry 57, 729-738.
43. Mathalon, D. H., and Ford, J. M. (2012). Neurobiology of schizophrenia: search for the elusive correlation with symptoms. Front. Hum. Neurosci. 6:136. doi:10.3389/fnhum.2012.00136
44. McIntyre, R. S., and O'Donovan, C. (2004). The human cost of not achieving full remission in depression. Can. J. Psychiatry 49, 10S-16S.
45. McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78, 804-814.
46. Meltzer, H. Y., and Lowy, M. T. (1987). "Theserotoninhypothesisof depression," in Psychopharmacology: The Third Generation of Progress, eds H. Y. Meltzer (New York: Raven Press), 513-526.
47. Meyer, J. H. (2007). Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 32, 86-102.
48. Meyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., et al. (2009a). Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 66, 1304-1312.
49. Meyer, P. M., Strecker, K., Kendziorra, K.,Becker,G.,Hesse,S.,Woelpl,D.,et al. (2009b). Reduced alpha4beta2*nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry 66, 866-877.
50. Millan, M. J. (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110, 135-370.
51. Millan, M. K. (2009). Dualand triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6, 53-77.
52. Miller, J. M., Brennan, K. G., Ogden, T. R., Oquendo, M. A., Sullivan, G. M., Mann, J. J., et al. (2009a). Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 34, 2275-2284.
53. Miller, J. M., Kinnally, E. L., Ogden, R. T., Oquendo, M. A., Mann, J. J., and Parsey, R. V. (2009b). Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse 63, 565-573.
54. Mineur, Y. S., and Picciotto, M. R. (2010). Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol. Sci. 31, 580-586.
55. Minichino, A., Bersani, F. S., Capra, E., Pannese, R., Bonanno, C., Salviati, M., et al. (2012). ECT, rTMS, and deepTMS in pharmacoresistant drug-free patients with unipolar depression: a comparative review. Neuropsychiatr. Dis. Treat. 8, 55-64.
56. Moller, M., Jakobsen, S., and Gjedde, A. (2007). Parametric and regional maps of free serotonin 5HT1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology 32, 1707-1714.
57. Moreno, F. A., Gelenberg, A. J., Heninger, G. R., Potter, R. L., McKnight, K. M., Allen, J., et al. (1999). Tryptophan depletion and depressive vulnerability. Biol. Psychiatry 46, 498-505.
58. Murrough, J. W., Henry, S., Hu, J., Gallezot, J. D., Planeta-Wilson, B., Neumaier, J. F., et al. (2011). Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl.) 213, 547-553.
59. Murthy, N. V., Selvaraj, S., Cowen, P. J., Bhagwagar, Z., Riedel, W. J., Peers, P., et al. (2010). Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 52, 50-54.
60. Nabulsi, N., Huang,Y., Weinzimmer, D., Ropchan, J., Frost, J. J., McCarthy, T., et al. (2010). High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. Nucl. Med. Biol. 37, 205-214.
61. Nieuwenhuis, S., Forstmann, B. U., and Wagenmakers, E. J. (2011). Erroneous analyses of interactions in neuroscience: a problem of significance. Nat. Neurosci. 14, 1105-1107.
62. Parsey, R. V., Hastings, R. S., Oquendo, M. A., Huang, Y. Y., Simpson, N., Arcement, J., et al. (2006a). Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am. J. Psychiatry 163, 52-58.
63. Parsey, R. V., Oquendo, M. A., Ogden, R. T., Olvet, D. M., Simpson, N., Huang, Y. Y., et al. (2006b). Altered serotonin 1A binding in major depression: a [carbonyl-C11]WAY100635 positron emission tomography study. Biol. Psychiatry 59, 106-113.
64. Parsey, R. V., Ogden, R. T., Miller, J. M., Tin, A., Hesselgrave, N., Goldstein, E., et al. (2010). Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol. Psychiatry 68, 170-178.
65. Paykel, E. S., Brugha, T., and Fryers, T. (2005). Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol. 15, 411-423.
66. Perry, E. K., Morris, C. M., Court, J. A., Cheng, A., Fairbairn, A. F., McKeith, I. G., et al. (1995). Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64, 385-395.
67. Politis, M., Wu, K., Loane, C., Turkheimer, F. E., Molloy, S., Brooks, D. J., et al. (2010). Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75, 1920-1927.
68. Praschak-Rieder, N., Wilson, A. A., Hussey,D.,Carella,A.,Wei,C.,Ginovart, N., et al. (2005). Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol. Psychiatry 58, 825-830.
69. Reimold, M., Knobel, A., Rapp, M. A., Batra, A., Wiedemann, K., Strohle, A., et al. (2011). Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl.) 213, 563-572.
70. Romanelli, M. N., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., and Gualtieri, F. (2007). Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Chem Med Chem 2, 746-767.
71. Rosa-Neto, P., Diksic, M., Okazawa, H., Leyton, M., Ghadirian, N., Mzengeza, S., et al. (2004). Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch. Gen. Psychiatry 61, 556-563.
72. Rudolph, U., and Knoflach, F. (2011). Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 10, 685-697.
73. Saijo, T., Takano, A., Suhara, T., Arakawa, R., Okumura, M., Ichimiya, T., et al. (2010a). Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635. Int. J. Neuropsychopharmacol. 13, 785-791.
74. Saijo, T., Takano, A., Suhara, T., Arakawa, R., Okumura, M., Ichimiya, T., et al. (2010b). Electroconvulsive therapy decreases dopamine D(2) receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [(11)C]FLB 457. J. Clin. Psychiatry 71, 793-799.
75. Sari, Y. (2004). Serotonin1B receptors: from protein to physiological function and behavior. Neurosci. Biobehav. Rev. 28, 565-582.
76. Saylam, C., Ucerler, H., Kitis, O., Ozand, E., and Gonul, A. S. (2006). Reduced hippocampal volume in drug-free depressed patients. Surg. Radiol. Anat. 28, 82-87.
77. Shrestha, S., Hirvonen, J., Hines, C. S., Henter, I. D., Svenningsson, P., Pike, V. W., et al. (2012). Serotonin1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage 59, 3243-3251.
78. Simmons, J. P., Nelson, L. D., and Simonsohn, U. (2011). Falsepositive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. Psychol. Sci. 22, 1359-1366.
79. Small, G. W., Siddarth, P., Kepe, V., Ercoli, L. M., Burggren, A. C., Bookheimer, S. Y., et al. (2012). Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch. Neurol. 69, 215-222.
80. Smith, D. F. (1999). Neuroimaging of serotonin uptake sites and antidepressant binding sites in the thalamus of humans and 'higher' animals. Eur. Neuropsychopharmacol. 9, 537-544.
81. Smith, D. F., and Jakobsen, S. (2007). Stereoselective neuroimaging in vivo. Eur. Neuropsychopharmacol. 17, 507-522.
82. Smith, D. F., and Jakobsen, S. (2009). Molecular tools for assessing human depression by positron emission tomography. Eur. Neuropsychopharmacol. 19, 611-628.
83. Smith, D. F., and Miller, P. W. (2010). "Challenges for PET Neuroimaging of Major Depressive Disorder," in Neuroimaging, Chap. 4, ed. C. M. Del-Ben (Rijeka: Intechopen Online Press), 1-20.
84. Smith, D. F., Stork, B. S., Wegener, G., Ashkanian, M., Jakobsen, S., Bender, D., et al. (2009). [11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology (Berl.) 206, 133-140.
85. Smith, D. F., Stork, B. S., Wegener, G., Jakobsen, S., Bender, D., Audrain, H., et al. (2007). Receptor occupancy of mirtazapine determined by PET in healthy volunteers. Psychopharmacology (Berl.) 195, 131-138.
86. Sullivan, G. M., Ogden, R. T., Oquendo, M. A., Kumar, J. S., Simpson, N., Huang, Y. Y., et al. (2009). Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol. Psychiatry 66, 223-230.
87. Theodore, W. H., Hasler, G., Giovacchini, G., Kelley, K., Reeves-Tyer, P., Herscovitch, P., et al. (2007). Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 48, 1526-1530.
88. Theodore, W. H., Wiggs, E. A., Martinez,A. R., Dustin, I. H., Khan, O. I., Appel, S., et al. (2012). Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia 53, 129-133.
89. Turner, W. J. (1982). Dexamethasone suppression test: problems and promise. Biol. Psychiatry 17, 1-2.
90. Vardy, E. R., Hussain, I., and Hooper, N. M. (2006). Emerging therapeutics for Alzheimer's disease. Expert Rev. Neurother. 6, 695-704.
91. Vasic, N., Walter, H., Hose, A., and Wolf, R. C. (2008). Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. J. Affect. Disord. 109, 107-116.
92. Vul, E., Harris, C., Winkielman, P., and Pashler, H. (2009). Puzzlingly high correlations in fMRI studies of emotion, personality, and social cognition. Perspect. Psychol. Sci. 4, 274-290.
93. Wachtel, H. (1982). Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl.) 77, 309-316.
94. Wachtel, H. (1983). Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'monophosphate phosphodiesterase inhibitors. Neuropharmacology 22, 267-272.
95. Wevers, A. (2011). Localisation of pre and postsynaptic cholinergic markers in the human brain. Behav. Brain Res. 221, 341-355.
96. Yatham, L. N., Liddle, P. F., Lam, R. W., Zis, A. P., Stoessl, A. J., Sossi, V., et al.(2010). Effectof electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br. J. Psychiatry 196, 474-479.
97. Zanotti-Fregonara, P., Zoghbi, S. S., Liow, J. S., Luong, E., Boellaard, R., Gladding, R. L., et al. (2011). Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an imagederived input function. Neuroimage 54, 1903-1909.